A phase III Randomized Open-Label Multi-Center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation

Administered By

Awarded By

Contributors

Start/End

  • May 11, 2017 - September 16, 2019